Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H13N |
Molecular Weight | 135.2062 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](N)CC1=CC=CC=C1
InChI
InChIKey=KWTSXDURSIMDCE-QMMMGPOBSA-N
InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1
Molecular Formula | C9H13N |
Molecular Weight | 135.2062 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017078s048lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdfCurator's Comment: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021977lbl.pdf | https://www.drugs.com/ppa/lisdexamfetamine.html | https://www.ncbi.nlm.nih.gov/pubmed/27125257
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/017078s048lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208510lbl.pdf
Curator's Comment: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021977lbl.pdf | https://www.drugs.com/ppa/lisdexamfetamine.html | https://www.ncbi.nlm.nih.gov/pubmed/27125257
Lisdexamfetamine (LDX) is a d-amphetamine (d-AMPH) pro-drug used to treat Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastrointestinal tract and converted to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. Most common adverse reactions in children, adolescents and/or adults with ADHD were anorexia, anxiety, decreased appetite, decreased weight, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, and vomiting. Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents decrease amphetamine blood levels, while alkalinizing agents increase amphetamine blood levels. Needs to adjust Lisdexamfetamine dosage accordingly.
Originator
Sources: http://www.chemeurope.com/en/encyclopedia/dextroamphetamine.htmlhttp://adisinsight.springer.com/drugs/800020876
Curator's Comment: New River Pharmaceuticals was bought by Shire Pharmaceuticals
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0050432 |
|||
Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17239355 |
|||
Target ID: CHEMBL1893 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7751968 |
|||
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19244097 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VYVANSE Approved UseVYVANSE® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14.1) Launch Date1.17218882E12 |
|||
Primary | VYVANSE Approved UseVYVANSE® is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14.1) Launch Date1.17218882E12 |
|||
Primary | DEXEDRINE Approved UseNarcolepsy. Attention Deficit Disorder with Hyperactivity. As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met. Launch Date3.15532804E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
47.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18021493/ |
70 mg 1 times / day multiple, oral dose: 70 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LISDEXAMFETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
24.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9807980/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
36.6 ng/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
60.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18021493/ |
70 mg 1 times / day multiple, oral dose: 70 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LISDEXAMFETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
431 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9807980/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18021493/ |
70 mg 1 times / day multiple, oral dose: 70 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
LISDEXAMFETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
12.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9807980/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
12 h |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXTROAMPHETAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 13 - 17 n = 233 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 13 - 17 Sex: M+F Population Size: 233 Sources: Page: p.8 |
Disc. AE: Irritability, Decreased appetite... AEs leading to discontinuation/dose reduction: Irritability (1.3%) Sources: Page: p.8Decreased appetite (0.86%) Insomnia (0.86%) |
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: Page: e771 |
healthy, 17 n = 1 Health Status: healthy Age Group: 17 Sex: F Population Size: 1 Sources: Page: e771 |
Disc. AE: Delirium, Tachycardia... AEs leading to discontinuation/dose reduction: Delirium (acute) Sources: Page: e771Tachycardia Hypertension Tachypnea Creatine kinase increased (mild) |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Disc. AE: Insomnia, Tachycardia... AEs leading to discontinuation/dose reduction: Insomnia (2%) Sources: Page: p.8Tachycardia (1%) Irritability (1%) Hypertension (1%) Headache (1%) Anxiety (1%) Dyspnea (1%) |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 6 - 12 n = 218 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 6 - 12 Sex: M+F Population Size: 218 Sources: Page: p.8 |
Disc. AE: Ventricular hypertrophy, Tic... AEs leading to discontinuation/dose reduction: Ventricular hypertrophy (1%) Sources: Page: p.8Tic (1%) Vomiting (1%) Psychomotor hyperactivity (1%) Insomnia (1%) Rash (1%) |
30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents n = 78 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adolescents Population Size: 78 Sources: |
Other AEs: Decreased appetite, Insomnia... Other AEs: Decreased appetite (below serious, 29 patients) Sources: Insomnia (below serious, 7 patients) Weight decreased (below serious, 3 patients) Irritability (below serious, 6 patients) Fatigue (below serious, 4 patients) Nasopharyngitis (below serious, 2 patients) |
20 mg single, oral Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Other AEs: Nausea... |
50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Other AEs: Headache, Nausea... Other AEs: Headache (below serious, 4 patients) Sources: Nausea (below serious, 1 patient) Vomiting (below serious, 2 patients) |
70 mg single, oral Dose: 70 mg Route: oral Route: single Dose: 70 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Other AEs: Headache, Nausea... Other AEs: Headache (below serious, 2 patients) Sources: Nausea (below serious, 2 patients) |
70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Other AEs: Diarrhea, Dry mouth... Other AEs: Diarrhea (below serious, 6 patients) Sources: Dry mouth (below serious, 25 patients) Fatigue (below serious, 6 patients) Feeling jittery (below serious, 10 patients) Irritability (below serious, 8 patients) Upper respiratory tract infection (below serious, 5 patients) Heart rate increased (below serious, 4 patients) Weight decreased (below serious, 8 patients) Anorexia (below serious, 4 patients) Decreased appetite (below serious, 26 patients) Headache (below serious, 20 patients) Initial insomnia (below serious, 8 patients) Insomnia (below serious, 10 patients) Libido decreased (below serious, 4 patients) Hyperhidrosis (below serious, 5 patients) |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Disc. AE: Abuse, Dependence... AEs leading to discontinuation/dose reduction: Abuse Sources: Page: p.1Dependence Cardiovascular disorder (NOS) (grade 3-5) Stroke (serious) Myocardial infarction (serious) Blood pressure increased Heart rate increased Psychiatric symptom NOS Psychotic symptom Manic symptom Growth suppression Vascular disorders Raynaud's phenomenon Serotonin syndrome |
50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Other AEs: Decreased appetite, Dry mouth... Other AEs: Decreased appetite (below serious, 8 patients) Sources: Dry mouth (below serious, 7 patients) Insomnia (below serious, 10 patients) Irritability (below serious, 3 patients) Diaphoresis (below serious, 2 patients) Libido decreased (below serious, 2 patients) Tinnitus (below serious, 2 patients) Muscle tension (below serious, 4 patients) Tachycardia (below serious, 3 patients) Paresthesia (below serious, 2 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Decreased appetite | 0.86% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 13 - 17 n = 233 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 13 - 17 Sex: M+F Population Size: 233 Sources: Page: p.8 |
Insomnia | 0.86% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 13 - 17 n = 233 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 13 - 17 Sex: M+F Population Size: 233 Sources: Page: p.8 |
Irritability | 1.3% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 13 - 17 n = 233 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 13 - 17 Sex: M+F Population Size: 233 Sources: Page: p.8 |
Hypertension | Disc. AE | 1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: Page: e771 |
healthy, 17 n = 1 Health Status: healthy Age Group: 17 Sex: F Population Size: 1 Sources: Page: e771 |
Tachycardia | Disc. AE | 1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: Page: e771 |
healthy, 17 n = 1 Health Status: healthy Age Group: 17 Sex: F Population Size: 1 Sources: Page: e771 |
Tachypnea | Disc. AE | 1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: Page: e771 |
healthy, 17 n = 1 Health Status: healthy Age Group: 17 Sex: F Population Size: 1 Sources: Page: e771 |
Delirium | acute Disc. AE |
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: Page: e771 |
healthy, 17 n = 1 Health Status: healthy Age Group: 17 Sex: F Population Size: 1 Sources: Page: e771 |
Creatine kinase increased | mild Disc. AE |
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: Page: e771 |
healthy, 17 n = 1 Health Status: healthy Age Group: 17 Sex: F Population Size: 1 Sources: Page: e771 |
Anxiety | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Dyspnea | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Headache | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Hypertension | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Irritability | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Tachycardia | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Insomnia | 2% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 18 - 55 n = 358 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 18 - 55 Sex: M+F Population Size: 358 Sources: Page: p.8 |
Insomnia | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 6 - 12 n = 218 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 6 - 12 Sex: M+F Population Size: 218 Sources: Page: p.8 |
Psychomotor hyperactivity | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 6 - 12 n = 218 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 6 - 12 Sex: M+F Population Size: 218 Sources: Page: p.8 |
Rash | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 6 - 12 n = 218 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 6 - 12 Sex: M+F Population Size: 218 Sources: Page: p.8 |
Tic | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 6 - 12 n = 218 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 6 - 12 Sex: M+F Population Size: 218 Sources: Page: p.8 |
Ventricular hypertrophy | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 6 - 12 n = 218 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 6 - 12 Sex: M+F Population Size: 218 Sources: Page: p.8 |
Vomiting | 1% Disc. AE |
70 mg 1 times / day multiple, oral (max) Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.8 |
unhealthy, 6 - 12 n = 218 Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder Age Group: 6 - 12 Sex: M+F Population Size: 218 Sources: Page: p.8 |
Nasopharyngitis | below serious, 2 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents n = 78 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adolescents Population Size: 78 Sources: |
Decreased appetite | below serious, 29 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents n = 78 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adolescents Population Size: 78 Sources: |
Weight decreased | below serious, 3 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents n = 78 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adolescents Population Size: 78 Sources: |
Fatigue | below serious, 4 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents n = 78 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adolescents Population Size: 78 Sources: |
Irritability | below serious, 6 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents n = 78 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adolescents Population Size: 78 Sources: |
Insomnia | below serious, 7 patients | 30 mg 1 times / day steady, oral Dose: 30 mg, 1 times / day Route: oral Route: steady Dose: 30 mg, 1 times / day Sources: |
unhealthy, adolescents n = 78 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adolescents Population Size: 78 Sources: |
Nausea | below serious, 1 patient | 20 mg single, oral Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Nausea | below serious, 1 patient | 50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Vomiting | below serious, 2 patients | 50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Headache | below serious, 4 patients | 50 mg single, oral Dose: 50 mg Route: oral Route: single Dose: 50 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Headache | below serious, 2 patients | 70 mg single, oral Dose: 70 mg Route: oral Route: single Dose: 70 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Nausea | below serious, 2 patients | 70 mg single, oral Dose: 70 mg Route: oral Route: single Dose: 70 mg Sources: |
healthy, adult n = 27 Health Status: healthy Condition: Acute Sleep Loss Age Group: adult Sex: M Population Size: 27 Sources: |
Feeling jittery | below serious, 10 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Insomnia | below serious, 10 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Headache | below serious, 20 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Dry mouth | below serious, 25 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Decreased appetite | below serious, 26 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Anorexia | below serious, 4 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Heart rate increased | below serious, 4 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Libido decreased | below serious, 4 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Hyperhidrosis | below serious, 5 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Upper respiratory tract infection | below serious, 5 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Diarrhea | below serious, 6 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Fatigue | below serious, 6 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Initial insomnia | below serious, 8 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Irritability | below serious, 8 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Weight decreased | below serious, 8 patients | 70 mg 1 times / day steady, oral (max) Dose: 70 mg, 1 times / day Route: oral Route: steady Dose: 70 mg, 1 times / day Sources: |
unhealthy, adult n = 79 Health Status: unhealthy Condition: Attention-Deficit/Hyperactivity Disorder Age Group: adult Population Size: 79 Sources: |
Abuse | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Blood pressure increased | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Dependence | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Growth suppression | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Heart rate increased | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Manic symptom | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Psychiatric symptom NOS | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Psychotic symptom | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Raynaud's phenomenon | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Serotonin syndrome | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Vascular disorders | Disc. AE | 70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Cardiovascular disorder (NOS) | grade 3-5 Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Myocardial infarction | serious Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Stroke | serious Disc. AE |
70 mg 1 times / day multiple, oral Recommended Dose: 70 mg, 1 times / day Route: oral Route: multiple Dose: 70 mg, 1 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Attention Deficit Hyperactivity Disorder|Binge Eating Disorder Sources: Page: p.1 |
Insomnia | below serious, 10 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Diaphoresis | below serious, 2 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Libido decreased | below serious, 2 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Paresthesia | below serious, 2 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Tinnitus | below serious, 2 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Irritability | below serious, 3 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Tachycardia | below serious, 3 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Muscle tension | below serious, 4 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Dry mouth | below serious, 7 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Decreased appetite | below serious, 8 patients | 50 mg 1 times / day steady, oral (max) Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy n = 28 Health Status: unhealthy Condition: Major Depressive Disorder Population Size: 28 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
Page: 7, 78 |
no [Inhibition 87.3 uM] | |||
Page: 7, 78 |
no [Inhibition 89 uM] | |||
Page: 7, 78 |
no [Inhibition 90 uM] | |||
Page: 7, 78 |
no [Inhibition 90.8 uM] | |||
Page: 7, 78 |
no [Inhibition 92.1 uM] | |||
Page: 7, 78 |
no [Inhibition 92.5 uM] | |||
Page: 7, 78 |
no [Inhibition 94.2 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 4.0 |
likely | likely (co-administration study) Comment: Amphetamines and amphetamine derivatives are known to be metabolized, to some degree, by cytochrome P450 2D6 (CYP2D6) and display minor inhibition of CYP2D6 metabolism; concomitant use of DEXEDRINE and CYP2D6 inhibitors may increase the exposure of DEXEDRINE; Page: 4.0 |
||
Page: 21.0 |
no |
PubMed
Title | Date | PubMed |
---|---|---|
Agonist and antagonist activity of low efficacy D2 dopamine receptor agonists in rats discriminating d-amphetamine from saline. | 1992 Dec |
|
Psychostimulants, adult attention deficit hyperactivity disorder and morbid jealousy. | 2000 Feb |
|
Dopaminergic mRNA expression in the intact substantia nigra of unilaterally 6-OHDA-lesioned and grafted rats: an in situ hybridization study. | 2001 |
|
No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy). | 2001 |
|
The purinergic P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2'4'-disulphonic acid prevents both the acute locomotor effects of amphetamine and the behavioural sensitization caused by repeated amphetamine injections in rats. | 2001 |
|
Determination of amphetamine in dog plasma by gas chromatography with mass selective detection. | 2001 Apr |
|
A nitric oxide-dopamine link pathway in organum vasculosum laminae terminalis of rat brain exerts control over blood pressure. | 2001 Apr |
|
Effect of 6-hydroxydopamine or repeated amphetamine treatment on mesencephalic mRNA levels for AMPA glutamate receptor subunits in the rat. | 2001 Apr 20 |
|
Interleukin-2 potentiates novelty- and GBR 12909-induced exploratory activity. | 2001 Apr 27 |
|
Tyrosine improves behavioral and neurochemical deficits caused by cold exposure. | 2001 Feb |
|
Differences in locomotor response to an inescapable novel environment predict sensitivity to aversive effects of amphetamine. | 2001 Feb |
|
Effects of acute D-amphetamine and ketamine on the performance of rats in a serial negative patterning procedure. | 2001 Feb |
|
The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered. | 2001 Feb |
|
Chronic inositol increases striatal D(2) receptors but does not modify dexamphetamine-induced motor behavior. Relevance to obsessive-compulsive disorder. | 2001 Feb |
|
Transcranial magnetic stimulation in an amphetamine hyperactivity model of mania. | 2001 Feb |
|
Comparison of the effects of infant handling, isolation, and nonhandling on acoustic startle, prepulse inhibition, locomotion, and HPA activity in the adult rat. | 2001 Feb |
|
Conditioned activity to amphetamine in transgenic mice expressing an antisense RNA against the glucocorticoid receptor. | 2001 Feb |
|
Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse. | 2001 Feb |
|
Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users. | 2001 Feb 15 |
|
Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. | 2001 Feb 16 |
|
Analysis of benzphetamine and its metabolites in rat urine by liquid chromatography-electrospray ionization mass spectrometry. | 2001 Feb 25 |
|
Striatal dopamine sensitization to D-amphetamine in periadolescent but not in adult rats. | 2001 Jan |
|
Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans. | 2001 Jan |
|
Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. | 2001 Jan |
|
Modification of d-amphetamine-induced responses by baclofen in rats. | 2001 Jan |
|
[Analysis of the striato-pallidal interactions in regulation of avoidance behavior]. | 2001 Jan |
|
Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity. | 2001 Jan |
|
Influence of time in culture and BDNF pretreatment on survival and function of grafted embryonic rat ventral mesencephalon in the 6-OHDA rat model of Parkinson's disease. | 2001 Jan |
|
What is a "low dose" of d-amphetamine for inducing behavioral effects in laboratory rats? | 2001 Jan 1 |
|
Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. | 2001 Jan 15 |
|
Environmental novelty differentially affects c-fos mRNA expression induced by amphetamine or cocaine in subregions of the bed nucleus of the stria terminalis and amygdala. | 2001 Jan 15 |
|
Significance of glutamate and dopamine neurons in the ventral pallidum in the expression of behavioral sensitization to amphetamine. | 2001 Jan 19 |
|
Fetal intra-nigral ventral mesencephalon and kidney tissue bridge transplantation restores the nigrostriatal dopamine pathway in hemi-parkinsonian rats. | 2001 Jan 19 |
|
Behavioural and anti-psychotic effects of Ca2+ channel blockers in rhesus monkey. | 2001 Jan 26 |
|
Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice. | 2001 Jan 8 |
|
Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. | 2001 Jan 8 |
|
Computer-aided screening for hallucinogenic and stimulant amphetamines with gas chromatography-Fourier transform infrared spectroscopy (GC-FTIR). | 2001 Jan-Feb |
|
The weaver mutant mouse: a model to study the ontogeny of dopamine transmission systems and their role in drug addiction. | 2001 Jun |
|
Effects of d-amphetamine on the performance of rats in an animal analogue of the A-X continuous performance test. | 2001 Mar |
|
Amphetamine selectively blocks inhibitory glutamate transmission in dopamine neurons. | 2001 Mar |
|
Seizure activity and hyperthermia potentiate the increases in dopamine and serotonin extracellular levels in the amygdala during exposure to d-amphetamine. | 2001 Mar |
|
Expression of sensitization to amphetamine and dynamics of dopamine neurotransmission in different laminae of the rat medial prefrontal cortex. | 2001 Mar |
|
Previous exposure to amphetamine enhances the subsequent locomotor response to a D1 dopamine receptor agonist when glutamate reuptake is inhibited. | 2001 Mar 1 |
|
Dopaminergic role in stimulant-induced wakefulness. | 2001 Mar 1 |
|
Dissociations between the effects of intra-accumbens administration of amphetamine and exposure to a novel environment on accumbens dopamine and cortical acetylcholine release. | 2001 Mar 16 |
|
Serotonin transporter localization in the hamster suprachiasmatic nucleus. | 2001 Mar 2 |
|
Amphetamine normalizes the electrical activity of dopamine neurons in the ventral tegmental area following prenatal ethanol exposure. | 2001 May |
|
Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. | 2001 May 1 |
|
Genes in drug abuse. | 2001 May 1 |
|
Post-training injections of catecholaminergic drugs do not modulate fear conditioning in rats and mice. | 2001 May 4 |
Sample Use Guides
Usual dose is 5 to 60 mg per day in divided doses, depending on the individual patient response. Narcolepsy seldom occurs in children under 12 years of age; however, when it does, DEXEDRINE may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until an optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily; daily dosage may be raised in increments of 10 mg at weekly intervals until an optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. SPANSULE capsules may be used for once-a-day dosage wherever appropriate.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6428136
Curator's Comment: The action of several concentrations of d-amphetamine on the NADH-tetrazolium reductase histochemical reaction has been studied in several nervous regions of rats. The facts observed have demonstrated that d-amphetamine increases the intensity of the histochemical reaction by its action on NADH-oxido-reductase activity in all nervous regions studied.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:43:37 UTC 2023
by
admin
on
Wed Jul 05 22:43:37 UTC 2023
|
Record UNII |
TZ47U051FI
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN06BA02
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
||
|
CFR |
21 CFR 310.502
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
||
|
WHO-ATC |
N06BA02
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
||
|
NDF-RT |
N0000175739
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
||
|
NCI_THESAURUS |
C47795
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
||
|
EPA PESTICIDE CODE |
600005
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
||
|
LIVERTOX |
293
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
||
|
NDF-RT |
N0000175729
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3288
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | RxNorm | ||
|
DTXSID8022907
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
TZ47U051FI
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
51-64-9
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
73713
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
4469
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
1430
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
841
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
CHEMBL612
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
TZ47U051FI
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
Dextroamphetamine
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
SUB07019MIG
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
100000088421
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
DB01576
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
DEXTROAMPHETAMINE
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
5826
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
200-112-1
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
M4226
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | Merck Index | ||
|
2147
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
D003913
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
C28981
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY | |||
|
3055
Created by
admin on Wed Jul 05 22:43:37 UTC 2023 , Edited by admin on Wed Jul 05 22:43:37 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
Adult PHARMACOKINETIC |
|
||
Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||